...
机译:CTLA4启动子甲基化预测抗CTLA-4免疫疗法(IPILIMIMAB)治疗的IV阶段Melanoma中的反应和无进展存活
Univ Hosp Bonn Dept Dermatol &
Allergy Venusberg Campus D-53127 Bonn Germany;
Univ Hosp Bonn Dept Otolaryngol Head &
Neck Surg Venusberg Campus D-53127 Bonn Germany;
Univ Hosp Bonn Dept Dermatol &
Allergy Venusberg Campus D-53127 Bonn Germany;
Tech Univ Munich Dept Dermatol &
Allergy Munich Germany;
Univ Hosp Bonn Dept Oncol Hematol &
Rheumatol Bonn Germany;
Univ Hosp Bonn Inst Neuropathol Bonn Germany;
Univ Hosp Bonn Dept Otolaryngol Head &
Neck Surg Venusberg Campus D-53127 Bonn Germany;
Univ Hosp Bonn Inst Neuropathol Bonn Germany;
Univ Hosp Bonn Inst Pathol Bonn Germany;
Univ Hosp Bonn Dept Otolaryngol Head &
Neck Surg Venusberg Campus D-53127 Bonn Germany;
Univ Hosp Bonn Dept Dermatol &
Allergy Venusberg Campus D-53127 Bonn Germany;
Univ Hosp Bonn Dept Otolaryngol Head &
Neck Surg Venusberg Campus D-53127 Bonn Germany;
CTLA-4; CTLA4; DNA methylation; Immunotherapy; Predictive biomarker; Melanoma;
机译:肿瘤浸润淋巴细胞在第III期的淋巴结转移中,对应于IV阶段疾病时患有IPILIMIMAB治疗的九患者的反应和生存
机译:MGMT启动子甲基化与替莫唑胺反应和弥漫性皮肤黑色素瘤的无进展生存期延长有关
机译:MgMT启动子甲基化与蜕皮素反应和弥漫性皮肤黑素瘤的延长进展存活有关
机译:放射组学诺模图的开发和验证,用于IV期EGFR突变非小细胞肺癌的无进展生存期预测
机译:治疗IV期非小细胞肺癌的费用和生存分析。
机译:CTLA4甲基化可预测黑色素瘤患者对抗PD-1和抗CTLA-4免疫疗法的反应
机译:CTLA4启动子甲基化预测抗CTLA-4免疫疗法(IPILIMIMAB)治疗阶段IV静脉瘤的反应和无进展存活